Time to onset of cannabidiol treatment effect and resolution of adverse events in tuberous sclerosis complex: Post hoc analysis of randomized controlled phase 3 trial GWPCARE6

OBJECTIVE: To estimate the timing of cannabidiol (CBD) treatment effect (seizure reduction and adverse events [AEs]) onset, we conducted a post hoc analysis of GWPCARE6 (NCT02544763), a randomized, placebo‐controlled, phase 3 trial in patients with drug‐resistant epilepsy associated with tuberous sc...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Joyce Y., Cock, Hannah R., Devinsky, Orrin, Joshi, Charuta, Miller, Ian, Roberts, Colin M., Sanchez‐Carpintero, Rocio, Checketts, Daniel, Sahebkar, Farhad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314914/
https://www.ncbi.nlm.nih.gov/pubmed/35175622
http://dx.doi.org/10.1111/epi.17199

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314914/
https://www.ncbi.nlm.nih.gov/pubmed/35175622
http://dx.doi.org/10.1111/epi.17199

Ejemplares similares